Hormone therapy for menopause: the complete guide

Menopausal hormone therapy replaces the estrogen the ovaries stop producing, and it is the most effective treatment available for hot flashes and night sweats. It usually means body-identical estradiol, paired with progesterone when you still have a uterus. Guidelines support it for healthy women under 60 or within 10 years of menopause onset, where benefits generally outweigh risks.

What is menopausal hormone therapy?

Menopausal hormone therapy (MHT, still widely called HRT) is the use of prescription estrogen, with or without a progestogen, to treat the symptoms caused by the decline in ovarian hormone production around menopause. The logic is simple: most of the classic menopause symptoms are downstream of falling and fluctuating estrogen, so restoring estrogen to a modest, steady level addresses the cause rather than each symptom in isolation. That is why one therapy can improve hot flashes, sleep, vaginal comfort, and bone density at the same time.

The estrogen used in mainstream modern therapy is estradiol, described as body-identical because its molecular structure matches the estradiol a woman's own ovaries produce. Progesterone is likewise available in a body-identical micronized form. Neither term implies a product is safer or gentler than any other option: it describes chemistry, not risk. Therapy can begin during perimenopause, when periods are still happening but symptoms have started, and it can begin after periods have stopped entirely. Menopause is diagnosed from your symptoms and history, so routine hormone bloodwork is not required to start.

Which menopause symptoms does hormone therapy treat, and how well?

Hormone therapy is not equally effective for everything women experience in midlife, and an honest guide has to say where the evidence is strong and where it is softer. Vasomotor symptoms (hot flashes and night sweats) and genitourinary symptoms respond best, because both are directly driven by estrogen loss. Sleep and mood often improve, but frequently as a consequence of the night sweats settling rather than as a direct hormonal effect. Other midlife complaints have weaker or mixed evidence, and no responsible clinician will promise they will resolve.

Two practical points follow from that table. First, if flashes and night sweats are what is wrecking your days, systemic therapy is the intervention with the best evidence behind it, and there is more detail in the guide to treating hot flashes. Second, genitourinary syndrome of menopause behaves differently from the rest: it tends to worsen over time rather than settle on its own, and it often responds to low-dose vaginal estrogen used locally, at doses far below systemic therapy. Some women need only the local treatment, some need only systemic, and some use both.

Why is hormone therapy usually estrogen plus progesterone?

Estrogen is the component that treats the symptoms. Progesterone is added for a different reason: protection. Estrogen given on its own stimulates the endometrium, the lining of the uterus, and unopposed stimulation over time raises the risk of endometrial hyperplasia and endometrial cancer. Adding a progestogen counteracts that stimulation and keeps the lining stable. This is not an optional extra or a matter of preference. If you have a uterus and you are taking systemic estrogen, endometrial protection is part of the prescription.

The practical consequence is that women who have had a hysterectomy generally take estrogen alone, while women with a uterus take a two-part regimen. The progestogen can be body-identical micronized progesterone, taken as a nightly capsule, or a synthetic progestin, and the two are not interchangeable in their side-effect profiles. Regimens are also either continuous (both hormones every day, aiming for no bleeding) or cyclical (progesterone for part of each month, producing a predictable withdrawal bleed), and cyclical dosing is often the better fit earlier in the transition when cycles have not fully stopped.

How do the estrogen delivery routes compare?

Route is one of the most consequential decisions in the whole prescription, and it is the one women are least often told about. Estrogen taken by mouth is absorbed through the gut and passes through the liver before it reaches the rest of the body, which alters clotting factors. Estrogen absorbed through the skin enters the bloodstream directly and largely bypasses that first pass through the liver. That single difference is why transdermal delivery is often preferred for women with clot risk factors, and there is a fuller breakdown in the estradiol guide.

No single route is correct for everyone. A woman with migraine with aura, a history of clot, high blood pressure or a raised BMI is often steered toward a transdermal option, while a woman with none of those and a preference for a daily tablet may reasonably take one. Local vaginal estrogen sits in its own category: it is the treatment for genitourinary syndrome of menopause, it can be used alongside systemic therapy, and because absorption is minimal it is frequently appropriate for women who cannot or do not want to take systemic hormones.

What did the WHI study change, and what changed back?

Almost every fear women bring to this conversation traces back to one study. In 2002, the Women's Health Initiative stopped the arm of its trial that combined oral conjugated equine estrogens with a synthetic progestin, reporting increased risks of breast cancer, coronary heart disease, stroke and blood clots, alongside fewer fractures and less colorectal cancer. The trial was large and rigorous and its findings were real. What went wrong was the translation to the public: the results were reported as relative risks, stripped of the absolute numbers that would have shown how small the change was for any individual woman.

The second problem was who was studied. The average participant was roughly 63 years old and many were more than a decade past their final period, whereas the women who actually seek treatment for symptoms are typically in their late 40s and early 50s. Cardiovascular risk in particular behaves differently in a woman starting therapy at 52 than in one starting at 63 with more established arterial change. Later age-stratified analyses produced what is now called the timing hypothesis: the benefit-risk balance is considerably more favorable when therapy begins near menopause onset than when it begins many years later. The full account is in the WHI study explained.

The result is that guidance today is neither the pre-2002 enthusiasm nor the post-2002 alarm. It is conditional and bounded, and it turns on age, timing and individual history rather than on a blanket verdict about hormones.

Who is a candidate for hormone therapy, and who is not?

There is no universal answer, which is why the decision belongs to you and a licensed clinician together rather than to an algorithm. That said, the profile of a typical candidate is reasonably well defined, and so is the list of conditions that make systemic hormone therapy inappropriate. The table below sets out both honestly. A contraindication is not a judgment about you: it means the risk calculation lands differently and a different plan is needed.

The middle category matters more than it looks. Many of the factors listed there are not absolute barriers: they shift the choice of route, the dose, or the level of monitoring. Migraine with aura, for example, usually points toward transdermal rather than oral estrogen instead of ruling therapy out. This is exactly the kind of judgment a clinician makes in conversation with you, and it is why prescribing is never guaranteed in advance.

What are the benefits beyond symptom relief?

The bone effect is the most substantial benefit that is not a symptom. Bone loss accelerates sharply in the years around the final period because estrogen restrains the cells that break bone down. Systemic hormone therapy prevents that accelerated loss and reduces fracture risk, which is why the major position statements list bone protection alongside vasomotor symptoms as an established benefit rather than a side effect. For a woman with symptoms who also has risk factors for osteoporosis, that benefit is a genuine part of the calculation.

Two honest caveats belong here. Hormone therapy is not prescribed to healthy women purely as a heart-disease prevention strategy, and it is not a treatment for cognitive decline: guidelines are explicit on both points. And the bone benefit largely persists only while therapy continues, so stopping does not lock in the gains permanently. What the evidence supports is a real, meaningful skeletal benefit in women who are taking therapy for symptoms anyway, not a reason to take hormones you otherwise do not need.

What are the real risks of hormone therapy?

Hormone therapy is not simply safe, and any page that tells you it is has stopped being useful. It carries real risks that vary by formulation, route, age and how long after menopause you begin. Stated plainly, and with absolute framing wherever the data allow it, these are the risks that matter.

• Breast cancer: combined estrogen and progestogen therapy is associated with a small increase in risk that emerges with longer duration of use. In absolute terms the WHI reported a small number of additional cases per 10,000 women per year. Estrogen-alone therapy in women without a uterus did not show the same signal.
• Blood clots: systemic estrogen raises the risk of venous thromboembolism, and the increase is consistently smaller with transdermal routes than with oral tablets, because transdermal estrogen largely bypasses first-pass liver metabolism.
• Stroke: a small absolute increase has been reported, concentrated in older women and in those starting therapy well after menopause rather than near its onset.
• Endometrial cancer: a real risk of unopposed systemic estrogen in a woman with a uterus, and the specific reason a progestogen is prescribed alongside it.
• Gallbladder disease: more commonly associated with oral estrogen than with transdermal delivery.
• Common early side effects: breast tenderness, bloating, headache, nausea and irregular spotting. These are usually settling or dose-related rather than dangerous, but they should be reported so the dose or route can be adjusted.

The way to read every one of those is in absolute terms, for a woman your age, starting at your point in the transition. A relative-risk percentage tells you almost nothing about your own odds without the baseline rate attached to it. The deeper evidence review is in is hormone therapy safe, which walks through the numbers rather than summarizing them.

How long do women stay on hormone therapy?

There is no fixed stopping date, and the older advice to come off after five years regardless of circumstances has been retired. Current guidance is that duration should be individualized and revisited periodically rather than capped arbitrarily, because the balance of benefit and risk changes over time and differs between women. Some women use therapy for a few years while symptoms are at their worst and taper off comfortably. Others continue for longer with an annual review, particularly where symptoms return on stopping or where bone protection is part of the reason for treating.

Two situations are worth separating out. Women with premature or early menopause are generally advised to continue therapy at least until the average age of natural menopause, because the comparison is against normal hormone levels for their age rather than against no hormones at all. And low-dose vaginal estrogen for genitourinary symptoms is often continued long term, since those symptoms tend to return when treatment stops. Whichever pattern applies, the practical answer is a scheduled review with your clinician, not a countdown clock.

What are the non-hormonal alternatives?

Hormone therapy is not the only option, and for women with a contraindication or a clear preference against hormones there are alternatives with genuine evidence behind them. They are generally less effective than estrogen for vasomotor symptoms, which is the honest framing, but less effective is not the same as ineffective.

• Certain non-hormonal prescription medications, including some antidepressants at lower doses and a newer class that acts on the brain pathway involved in hot flashes.
• Cognitive behavioral therapy and clinical hypnosis, both of which have trial evidence for reducing how much hot flashes bother women.
• Vaginal moisturizers and lubricants for dryness and painful sex, used alone or alongside local estrogen.
• Practical measures: layered clothing, a cool bedroom, trigger awareness with alcohol and spicy food, regular exercise, weight management and stopping smoking.
• Bone-specific medications, where the main concern is osteoporosis rather than symptoms.

Over-the-counter supplements marketed for menopause are a different matter. Evidence for most of them is weak or inconsistent, they are not subject to the same manufacturing standards as prescription medication, and some interact with prescribed drugs. It is reasonable to discuss anything you are taking with your clinician rather than assuming a product is inert because it is sold without a prescription.

Are compounded bioidentical hormones better than standard therapy?

This deserves a careful answer, because the marketing around it is often misleading. Compounded preparations are medications prepared individually by a state-licensed 503A pharmacy, mixed for a specific patient's prescription rather than manufactured as a standardized commercial product. Compounding is a legitimate and long-established part of pharmacy practice, and it has real uses: a documented allergy to an excipient in a commercial product, or a dose or combination that is not commercially available.

What the evidence does not support is the claim that compounded hormones are safer, more natural or more effective than standardized therapy. They are not. Body-identical estradiol and micronized progesterone are available as standardized commercial products, so the word bioidentical describes the molecule and not the compounding process. Custom compounded preparations do not carry the same standardized batch testing or safety labeling, and salivary hormone testing marketed to guide their dosing is not a validated basis for adjusting therapy.

How do you start hormone therapy?

The path is short, and each step has a purpose. You complete a detailed symptom and health-history assessment so a clinician has the full picture. You then have a live video or phone visit with a US-licensed clinician, who reviews your history, discusses your goals and risks, and decides whether therapy is appropriate and, if so, which route and dose fit you. There is no in-person clinic visit, but the live visit is required and cannot be replaced by a questionnaire. If therapy is prescribed, medication is dispensed and shipped, and follow-up continues from there.

You do not need bloodwork to begin. Menopause is diagnosed from symptoms and history, and therapy is titrated by how you feel rather than by a target hormone level, though a clinician may suggest specific testing when it genuinely adds value for your situation. Expect the first few weeks to involve some adjustment: vasomotor symptoms often begin improving within weeks, genitourinary symptoms usually take longer, and early side effects frequently settle or resolve with a change of dose or route. Current pricing is listed on the pricing section of the treatments page.